JAK Inhibitors in Psoriatic Disease

References

• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Napolitano M, Caso F, Scarpa R, et al. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35(8):1893–1901. doi:10.1007/s10067-016-3295-9
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233. doi:10.3390/jcm12093233
   PubMed Web of Science ®Google Scholar
• Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35. doi:10.1186/1477-7525-4-35
   PubMed Web of Science ®Google Scholar
• Potestio L, Camela E, Cacciapuoti S, et al. Biologics for the management of erythrodermic psoriasis: an updated review. Clin Cosmet Investig Dermatol. 2023;16:2045–2059. doi:10.2147/CCID.S407813
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Ruggiero A, et al. Use of biological therapies for the management of pustular psoriasis: a new era? Clin Cosmet Investig Dermatol. 2023;16:1677–1690. doi:10.2147/CCID.S407812
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Caso F, Alivernini S, et al. Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease. Autoimmun Rev. 2019;18(6):565–575. doi:10.1016/j.autrev.2018.11.007
   PubMed Web of Science ®Google Scholar
• Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I. Psoriatic Disease 10 Years Later. J Rheumatol. 2017;44(9):1298–1301. doi:10.3899/jrheum.161402
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Toussirot E, Gallais-Sérézal I, Aubin F. The cardiometabolic conditions of psoriatic disease. Front Immunol. 2022;13:970371. doi:10.3389/fimmu.2022.970371
   PubMed Web of Science ®Google Scholar
• Caso F, Del Puente A, Oliviero F, et al. Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol. 2018;37(3):579–586. doi:10.1007/s10067-017-3975-0
   PubMed Web of Science ®Google Scholar
• Caso F, Chimenti MS, Navarini L, et al. Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. Expert Rev Clin Immunol. 2020;16(4):409–420. doi:10.1080/1744666X.2020.1740593
   PubMed Web of Science ®Google Scholar
• Ogdie A, Gelfand JM. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence. Curr Rheumatol Rep. 2015;17(10):64. doi:10.1007/s11926-015-0540-1
   PubMed Web of Science ®Google Scholar
• Mishra S, Kancharla H, Dogra S, Sharma A. Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study). Br J Dermatol. 2017;176(3):765–770. doi:10.1111/bjd.14929
   PubMed Web of Science ®Google Scholar
• Caso F, Postiglione L, Covelli B, et al. Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset “sine psoriasis”. Clin Rheumatol. 2019;38(9):2547–2552. doi:10.1007/s10067-019-04619-w
   PubMed Web of Science ®Google Scholar
• Tashiro T, Sawada Y. Psoriasis and Systemic Inflammatory Disorders. Int J Mol Sci. 2022;23(8):4457. doi:10.3390/ijms23084457
   PubMed Web of Science ®Google Scholar
• Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines. 2021;9(11):1511. doi:10.3390/biomedicines9111511
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34:e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35:e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Yang F, Lu C, Wang Y, Liu H, Leng X, Zeng X. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023;42(6):1593–1605. doi:10.1007/s10067-023-06529-4
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Triggianese P, et al. Recent developments for new investigational JAK inhibitors in psoriatic arthritis. Expert Opin Investig Drugs. 2023;32(5):361–371. doi:10.1080/13543784.2023.2207737
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
   PubMed Web of Science ®Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73. doi:10.1016/j.jaut.2015.07.008
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;1–16. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar
• Cacciapuoti S, Potestio L, Guerrasio G, et al. Effectiveness of brodalumab in patients with moderate-to-severe plaque psoriasis located in difficult-to-treat areas. Clin Cosmet Investig Dermatol. 2023;16:2637–2644. doi:10.2147/CCID.S423234
   PubMed Web of Science ®Google Scholar
• Singh S, Pradhan D, Puri P, et al. Genomic alterations driving psoriasis pathogenesis. Gene. 2019;683:61–71. doi:10.1016/j.gene.2018.09.042
   PubMed Web of Science ®Google Scholar
• Komine M, Freedberg IM, Blumenberg M. Regulation of epidermal expression of keratin K17 in inflammatory skin diseases. J Invest Dermatol. 1996;107(4):569–575. doi:10.1111/1523-1747.ep12582820
   PubMed Web of Science ®Google Scholar
• Zeng R, Spolski R, Casas E, Zhu W, Levy DE, Leonard WJ. The molecular basis of IL-21-mediated proliferation. Blood. 2007;109(10):4135–4142. doi:10.1182/blood-2006-10-054973
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Muromoto R, Akimoto T, et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol. 2014;26(5):257–267. doi:10.1093/intimm/dxt062
   PubMed Web of Science ®Google Scholar
• Azuaga AB, Ramírez J, Cañete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901. doi:10.3390/ijms24054901
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Chimenti MS, Navarini L, Punzi L. Pathogenesis of Psoriatic Arthritis. Crit Rev Immunol. 2019;39(5):361–377. doi:10.1615/CritRevImmunol.2020033243
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Napolitano M, et al. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses. 2020;143:109853. doi:10.1016/j.mehy.2020.109853
   PubMed Web of Science ®Google Scholar
• Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res. 2014;58(1):61–69. doi:10.1007/s12026-013-8481-0
   PubMed Web of Science ®Google Scholar
• Fiocco U, Martini V, Accordi B, et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol. 2015;34(9):1571–1580. doi:10.1007/s10067-015-3002-2
   PubMed Web of Science ®Google Scholar
• Fiocco U, Martini V, Accordi B, et al. Ex vivo signaling protein mapping in t lymphocytes in the psoriatic arthritis joints. J Rheumatol Suppl. 2015;93:48–52. doi:10.3899/jrheum.150636
   PubMedGoogle Scholar
• Caso F, Saviano A, Tasso M, et al. Analysis of rheumatoid- vs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3/4 and FOXP3) activation. Autoimmun Rev. 2022;21(12):103207. doi:10.1016/j.autrev.2022.103207
   PubMed Web of Science ®Google Scholar
• Navarini L, Currado D, Costa L, Tasso M, Chimenti MS, Caso F. Experimental and investigational pharmacotherapy for psoriatic arthritis: drugs of the future. J Exp Pharmacol. 2020;12:487–502. doi:10.2147/JEP.S265633
   PubMedGoogle Scholar
• Caso F, Navarini L, Ruscitti P, et al. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. Expert Opin Pharmacother. 2020;21(7):785–796. doi:10.1080/14656566.2020.1726317
   PubMed Web of Science ®Google Scholar
• Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–337. doi:10.1111/jdv.12106
   PubMed Web of Science ®Google Scholar
• Fernández-Torres RM, Paradela S, Fonseca E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatolog Treat. 2014;25(1):54–56. doi:10.3109/09546634.2012.755254
   PubMed Web of Science ®Google Scholar
• Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatology Venereol. 2022;157(Suppl. 1 to No. 1):1–78. doi:10.23736/S2784-8671.21.07132-2
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. doi:10.1111/jdv.16926
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi:10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Scarpa R, Caso F. Spondyloarthritis: which composite measures to use in psoriatic arthritis? Nat Rev Rheumatol. 2018;14(3):125–126. doi:10.1038/nrrheum.2018.15
   PubMed Web of Science ®Google Scholar
• Tucker LJ, Coates LC, Helliwell PS. Assessing Disease Activity in Psoriatic Arthritis: a Literature Review. Rheumatol Ther. 2019;6(1):23–32. doi:10.1007/s40744-018-0132-4
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023:1–17. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Costa L, Lubrano E, Ramonda R, et al. Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate. Clin Rheumatol. 2017;36(8):1797–1802. doi:10.1007/s10067-017-3697-3
   PubMed Web of Science ®Google Scholar
• Caso F, Tasso M, Chimenti MS, et al. Late-onset and elderly psoriatic arthritis: clinical aspects and management. Drugs Aging. 2019;36(10):909–925. doi:10.1007/s40266-019-00688-3
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35–55. doi:10.1007/s40259-022-00569-z
   PubMed Web of Science ®Google Scholar
• Caso F, Lubrano E, Del Puente A, et al. Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2016;12(3):315–331. doi:10.1586/1744666X.2016.1117941
   PubMed Web of Science ®Google Scholar
• Caso F, Del Puente A, Peluso R, et al. Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs. 2016;21(1):69–79. doi:10.1517/14728214.2016.1146679
   PubMed Web of Science ®Google Scholar
• Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences. Jt Bone Spine. 2023;90(1):105469. doi:10.1016/j.jbspin.2022.105469
   PubMed Web of Science ®Google Scholar
• Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D. 2017;17(4):509–522. doi:10.1007/s40268-017-0215-7
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Triggianese P, De Martino E, et al. An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Rev Clin Immunol. 2019;15(8):823–836. doi:10.1080/1744666X.2019.1627876
   PubMed Web of Science ®Google Scholar
• Zagaria O, Villani A, Ruggiero A, et al. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374. doi:10.1111/dth.15374
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2282. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459–472. doi:10.1007/s40265-017-0709-1
   PubMed Web of Science ®Google Scholar
• Costa L, Del Puente A, Peluso R, et al. Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother. 2017;18(15):1557–1567. doi:10.1080/14656566.2017.1378343
   PubMed Web of Science ®Google Scholar
• Martora F, Scalvenzi M, Ruggiero A, Potestio L, Battista T, Megna M. Hidradenitis suppurativa and JAK inhibitors: a review of the published literature. Medicina. 2023;59(4). doi:10.3390/medicina59040801
   PubMedGoogle Scholar
• Martora F, Scalvenzi M, Battista T, et al. Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data. Clin Cosmet Investig Dermatol. 2023;16:2525–2536. doi:10.2147/CCID.S418748
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–677. doi:10.1111/j.1365-2133.2012.11168.x
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961. doi:10.1111/bjd.14018
   PubMed Web of Science ®Google Scholar
• Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561. doi:10.1016/S0140-6736(14)62113-9
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luchi M, Fidelus-Gort R, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatolog Treat. 2016;27(4):332–338. doi:10.3109/09546634.2015.1115819
   PubMed Web of Science ®Google Scholar
• Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol. 2018;179(1):54–62. doi:10.1111/bjd.16004
   PubMed Web of Science ®Google Scholar
• Ludbrook VJ, Hicks KJ, Hanrott KE, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016;174(5):985–995. doi:10.1111/bjd.14399
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–1276. doi:10.1111/bjd.14403
   PubMed Web of Science ®Google Scholar
• Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173(3):767–776. doi:10.1111/bjd.13745
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Thaçi D, et al. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018;379(14):1313–1321. doi:10.1056/NEJMoa1806382
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. doi:10.1016/j.jaad.2022.07.002
   PubMed Web of Science ®Google Scholar
• Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. doi:10.1016/j.jaad.2022.08.061
   PubMed Web of Science ®Google Scholar
• Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and safety of brepocitinib (tyrosine kinase 2/janus kinase 1 inhibitor) for the treatment of active psoriatic arthritis: results from a phase 2b randomized controlled trial. Arthr Rheu. 2021;73:1009–1011.
   Google Scholar
• Tehlirian C, Singh RSP, Pradhan V, et al. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2022;87(2):333–342. doi:10.1016/j.jaad.2022.03.059
   PubMed Web of Science ®Google Scholar
• Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–730. doi:10.1080/1744666X.2018.1512404
   PubMed Web of Science ®Google Scholar
• Leung YY, Korotaeva T, Candia L, et al. Management of peripheral arthritis in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2022;49(12):1. doi:10.3899/jrheum.220315.C1
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017;377(16):1537–1550. doi:10.1056/NEJMoa1615975
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536. doi:10.1056/NEJMoa1615977
   PubMed Web of Science ®Google Scholar
• Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study. Rheumatol Ther. 2020;7(3):553–580. doi:10.1007/s40744-020-00209-4
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the Phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019;5(1):e000808. doi:10.1136/rmdopen-2018-000808
   PubMed Web of Science ®Google Scholar
• Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2018;5(2):567–582. doi:10.1007/s40744-018-0131-5
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Tofacitinib or Adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5(1):e000806. doi:10.1136/rmdopen-2018-000806
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline c-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or Adalimumab. J Rheumatol. 2019;46(9):1089–1096. doi:10.3899/jrheum.180971
   PubMed Web of Science ®Google Scholar
• Papp KA, Krueger JG, Feldman SR, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841–850. doi:10.1016/j.jaad.2016.01.013
   PubMed Web of Science ®Google Scholar
• Valenzuela F, Korman NJ, Bissonnette R, et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018;179(4):853–862. doi:10.1111/bjd.16798
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022;18(5):301–304. doi:10.1038/s41584-022-00767-7
   PubMed Web of Science ®Google Scholar
• Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7(2):e001595. doi:10.1136/rmdopen-2021-001595
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–326. doi:10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227–1239. doi:10.1056/NEJMoa2022516
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312–320. doi:10.1136/annrheumdis-2020-218870
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838. doi:10.1136/rmdopen-2021-001838
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kato K, Magrey M, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2023;10(1):275–292. doi:10.1007/s40744-022-00499-w
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study. Rheumatol Ther. 2021;8(2):903–919. doi:10.1007/s40744-021-00305-z
   PubMed Web of Science ®Google Scholar
• Strand V, Mease PJ, Soriano ER, et al. Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT-PsA 1. Rheumatol Ther. 2021;8(4):1789–1808. doi:10.1007/s40744-021-00379-9
   PubMed Web of Science ®Google Scholar
• Strand V, Van den Bosch F, Ranza R, et al. Patient-reported outcomes in psoriatic arthritis patients with an inadequate response to biologic disease-modifying antirheumatic drugs: SELECT-PsA 2. Rheumatol Ther. 2021;8(4):1827–1844. doi:10.1007/s40744-021-00377-x
   PubMed Web of Science ®Google Scholar
• Mease P, Kavanaugh A, Gladman D, et al. Disease control with upadacitinib in patients with psoriatic arthritis: a post hoc analysis of the randomized, placebo-controlled SELECT-PsA 1 and 2 phase 3 trials. Rheumatol Ther. 2022;9(4):1181–1191. doi:10.1007/s40744-022-00449-6
   PubMed Web of Science ®Google Scholar
• Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47(5):918–925. doi:10.1111/ced.15052
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Pavia G, et al. Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series. J Dermatolog Treat. 2023;34(1):2183729. doi:10.1080/09546634.2023.2183729
   PubMed Web of Science ®Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2367–2377. doi:10.1016/S0140-6736(18)32483-8
   PubMed Web of Science ®Google Scholar
• Orbai AM, Ogdie A, Gossec L, et al. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology. 2020;59(7):1495–1504. doi:10.1093/rheumatology/kez408
   PubMed Web of Science ®Google Scholar
• To evaluate the efficacy and safety of shr0302 tablet in subjects of active psoriatic arthritis. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04957550. Accessed October 16, 2023.
   Google Scholar
• Lé AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23(6):813–822. doi:10.1007/s40257-022-00720-0
   PubMed Web of Science ®Google Scholar
• Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502). doi:10.1126/scitranslmed.aaw1736
   Web of Science ®Google Scholar
• Thaçi D, Strober B, Gordon KB, et al. Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial. Dermatol Ther. 2022;12(2):495–510. doi:10.1007/s13555-021-00649-y
   PubMed Web of Science ®Google Scholar
• Warren RB, Sofen H, Imafuku S, et al. POS1046 deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 poetyk PSO program. Ann Rheum Dis. 2022;81:841. doi:10.1136/annrheumdis-2022-eular.2445
   Web of Science ®Google Scholar
• Imafuku S, Tada Y, Hippeli L, Banerjee S, Morita A, Ohtsuki M. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. J Dermatol. 2023;50(5):588–595. doi:10.1111/1346-8138.16740
   PubMed Web of Science ®Google Scholar
• Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–822. doi:10.1136/annrheumdis-2021-221664
   PubMed Web of Science ®Google Scholar
• Calabrese L, Malvaso D, Antonelli F, Mannino M, Peris K, Chiricozzi A. Investigational systemic drugs for moderate to severe plaque psoriasis: what’s new? Expert Opin Investig Drugs. 2023;32(3):229–243. doi:10.1080/13543784.2023.2184684
   PubMed Web of Science ®Google Scholar
• Martin G. Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors. Dermatol Ther (Heidelb). 2023;13(2):417–435. doi:10.1007/s13555-022-00878-9
   PubMed Web of Science ®Google Scholar
• Page KM, Suarez-Farinas M, Suprun M, et al. Molecular and cellular responses to the TYK2/JAK1 Inhibitor PF-06700841 reveal reduction of skin inflammation in plaque psoriasis. J Invest Dermatol. 2020;140(8):1546–1555.e4. doi:10.1016/j.jid.2019.11.027
   PubMed Web of Science ®Google Scholar
• Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase iia, randomized, double-blind, placebo-controlled trial. J Invest Dermatol. 2020;140(12):2359–2370.e5. doi:10.1016/j.jid.2020.03.962
   PubMed Web of Science ®Google Scholar
• Landis MN, Smith SR, Berstein G, et al. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study. Br J Dermatol. 2023;189(1):33–41. doi:10.1093/bjd/ljad098
   PubMed Web of Science ®Google Scholar
• Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J Clin Pharmacol. 2018;58(4):434–447. doi:10.1002/jcph.1046
   PubMed Web of Science ®Google Scholar
• Alumis Inc. A study to evaluate the efficacy and safety of ESK-001 in patients with plaque psoriasis. Available from: https://clinicaltrials.gov/study/NCT05600036?cond=Plaque%20Psoriasis&term=esk-001&rank=2. Accessed 10 July 2023.
   Google Scholar
• Takeda. A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis. https://clinicaltrials.gov/study/NCT05153148?cond=Psoriatic%20Arthritis&term=NDI-034858&rank=1. Accessed 10 July 2023.
   Google Scholar
• Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–1148. doi:10.1111/jocd.15543
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med. 2023;10:1243843. doi:10.3389/fmed.2023.1243843
   Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22:355–362. doi:10.1080/14740338.2023.2218086
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Annunziata MC, Fabbrocini G, Megna M. Face the COVID-19 emergency: measures applied in an Italian dermatologic clinic. J Eur Acad Dermatol Venereol. 2020;34(6):e249. doi:10.1111/jdv.16476
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, Ruggiero A. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’. Clin Exp Dermatol. 2022;47(10):1864–1865. doi:10.1111/ced.15291
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Fabbrocini G, Martora F. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47(10):1863–1864. doi:10.1111/ced.15286
   PubMed Web of Science ®Google Scholar